Gyre Therapeutics, Inc. (GYRE)

NASDAQ: GYRE · USD

$7.02

+0.49 (+7.5%)· Recorded snapshot

Market cap	744.4M
Revenue (ttm)	109.8M
Net income (ttm)	-19.9M
EPS (ttm)	-$0.22
Shares out	106M
Volume	106,007
Beta	4.74

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 109.8M
Net income (ttm): -19.9M
EPS (ttm): -$0.22
Market cap: 744.4M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Mantener

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-17.4

P25 n/aP50 n/aP75 n/a

ROIC-16.8

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All GYRE indicators

Market & fundamental data

Available fields

193

Groups with data

Currency

USD

Showing 193 of 193 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001124105
Company name	Gyre Therapeutics, Inc.
Country	United States
Country code	US
CUSIP number	403783103
Earnings date	2026-11-10
Earnings time	bmo
Employees	625
Employees change	46
Employees growth	7.94%
Enterprise value	$673M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2002
In index	RUSSELL2000
Industry	Biotechnology
Is primary listing	Yes
Is SPAC	No
ISIN number	US4037831033
Last 10-K release date	2026-03-13
Last earnings date	2026-08-07
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$744.4M
Market cap category	Small-Cap
Next earnings date	2026-11-10
Options	Yes
Price	$7.02
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	GYRE
U.S. state	California
Website	https://www.gyretx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-3.09%
EV/Sales	5.93x
FCF / EV yield	-0.94%
FCF yield	-0.85%
Forward EV/Sales	11.23x
Forward P/S	12.47x
P/B ratio	6.42x
P/S ratio	6.58x
Price / tangible book value	6.98x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	-13.9%
EBITDA margin	-11.05%
Gross margin	93.8%
Operating margin	-13.9%
Pretax margin	-20.3%
Profit margin	-19.33%
Profit per employee	$-31,853
Profitable years	2
Revenue per employee	$175,709
ROA	-5.42%
ROCE	-8.95%
ROE	-17.44%
ROIC	-16.81%
SBC / revenue	8.99%
Tax / revenue	3.08%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	0
Gross profit growth	-5.91%
Gross profit growth (Q)	-5.9%
Gross profit growth 3Y	-1.69%
Net income growth years	0
Revenue growth	-3.39%
Revenue growth (Q)	-2.12%
Revenue growth (QoQ)	19.14%
Revenue growth 3Y	-1.07%
Revenue growth years	1

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-1.2M
Depreciation and amortization	$3.1M
EBIT	$-15.3M
EBITDA	$-12.1M
EPS	$-0.22
FCF per share	$-0.06
Financing cash flow	$2.8M
Free cash flow	$-6.1M
Free cash flow minus SBC	$-16M
Gross profit	$103M
Income taxes	$3.4M
Investing cash flow	$2.9M
Net cash flow	$2M
Net income	$-19.9M
Operating cash flow minus SBC	$-14.8M
Operating income	$-15.3M
Revenue	$109.8M
Stock-based compensation	$9.9M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	11.85
Book value per share	$1.02
Debt / equity	0.02
Long-term assets	$77.2M
Long-term liabilities	$5.7M
Net cash (debt)	$71.4M
Net cash / market cap	9.88%
Net cash growth	34.75%
Net debt / equity	-0.43
Piotroski F-Score	1
Property, plant and equipment	$30.6M
Shareholders' equity	$164.9M
Tangible book value	$103.4M
Tangible book value per share	$0.98
Total assets	$199.3M
Total cash	$74.8M
Total debt	$3.4M
Total liabilities	$34.3M
WACC	30.15%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.62
Current assets	$122.1M
Current liabilities	$28.7M
Current ratio	4.26
Inventory turnover	0.67
Net working capital	$20M
Quick ratio	3.59
Working capital	$93.4M
Working capital turnover	1.31

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	1.16%
Dividend yield	0%
Shareholder yield	1.16%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$6.72
1D price change	7.5%
1M price change	-4.49%
1M total return	-4.49%
1W price change	18.98%
1W total return	18.98%
1Y price change	-12.47%
1Y return CAGR	-12.48%
1Y total return	-12.47%
20-day SMA	$6.57
200-day SMA	$7.01
3M price change	14.52%
3M total return	14.52%
50-day SMA	$6.80
50-day SMA vs 200-day SMA	50under200
52-week high	$9.14
52-week high date	2026-03-05
52-week low	$5.44
52-week low date	2026-06-02
6M price change	-7.99%
6M total return	-7.99%
All-time high	$30.40
All-time high date	2023-12-21
All-time low	$5.44
All-time low date	2026-06-02
Average true range (ATR)	$0.33
Average volume	124.8K
Beta (1Y)	1.6
Beta (2Y)	1.71
Beta (5Y)	4.74
Change from 52-week high	-23.19%
Change from 52-week low	29.04%
Change from all-time high	-76.91%
Change from all-time low	29.04%
Change from open	8.33%
Day's gap	-0.77%
Dollar volume	$744,169
High price	$7.06
Low price	$6.48
Monthly RSI	48.72
Open price	$6.48
Position in 52-week range	93.1%
Premarket change	0.61%
Premarket close	$6.53
Premarket price	$6.57
Premarket volume	108
Previous close	$6.53
Price vs 150-day SMA	4.51%
Price vs 20-day SMA	6.85%
Price vs 200-day SMA	0.14%
Price vs 50-day SMA	3.31%
Relative volume	0.86
RSI	58.57
Sharpe ratio	-0.03
Sortino ratio	0.06
Volume	106K
Weekly RSI	51.87
YTD price change	-0.57%
YTD total return	-0.57%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	35.9M
Float percentage	33.9%
Shares change (QoQ)	10.14%
Shares change (YoY)	-1.16%
Shares held by insiders	5.74%
Shares held by institutions	8.21%
Shares outstanding	106M
Short % of float	5.34%
Short % of shares	1.81%
Short ratio	10.4 days

Deeper analysis on GYRE

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this GYRE report

Is a complete GYRE research report available?

No complete published report is available for Gyre Therapeutics, Inc. (GYRE) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Gyre Therapeutics, Inc. (GYRE)

Price

Financial snapshot

Fair-value bridge

Latest news · GYRE

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All GYRE indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on GYRE

Frequently asked questions